Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Which specific bacteria have developed resistance to tigecycline?

See the DrugPatentWatch profile for tigecycline

Common Bacteria Resistant to Tigecycline


Tigecycline, a glycylcycline antibiotic, faces resistance primarily through efflux pumps, ribosomal protection, and enzymatic inactivation. Key resistant species include:

- Acinetobacter baumannii: High resistance rates, often >50% in ICU settings due to AdeABC efflux overexpression.[1]
- Pseudomonas aeruginosa: Intrinsic resistance from MexXY efflux and low outer membrane permeability.[2]
- Proteus spp. (e.g., Proteus mirabilis): Intrinsic resistance linked to poor accumulation.[3]
- Providencia spp.: Similarly intrinsically resistant via efflux mechanisms.[3]

Emerging and Variable Resistance Cases


Resistance has emerged in other Gram-negatives and Gram-positives under selective pressure:

- Enterobacterales like Klebsiella pneumoniae and Escherichia coli: Plasmid-mediated tet(X) enzymes degrade tigecycline; MICs >8 mg/L reported in 5-20% of isolates from China and India.[4][5]
- Stenotrophomonas maltophilia: Frequent resistance via SmeDEF efflux.[6]
- Enterococcus faecium: Rare but increasing via tet(L/M) genes; vancomycin-resistant strains often affected.[7]

Gram-positive cocci like Staphylococcus aureus and Streptococcus pneumoniae generally remain susceptible, though rare tet(X4)-producing MRSA cases exist.[5]

Mechanisms Driving Resistance


Efflux (e.g., TetA, MefA) predominates in Gram-negatives; ribosomal mutations (e.g., 16S rRNA) and tet(X) nucleotidotransferases confer high-level resistance. Resistance spreads via plasmids, complicating treatment of CRAB (carbapenem-resistant A. baumannii).[4]

Clinical Impact and Testing


Resistance limits tigecycline use in polymicrobial infections; EUCAST breakpoints flag MIC >2 mg/L as resistant. Surveillance shows rising rates in Asia (up to 30% for A. baumannii) vs. lower in Europe (<10%).[1][8]

Sources
[1]: CDC CRE Toolkit
[2]: PubMed - Pseudomonas tigecycline resistance
[3]: FDA Tigecycline Label
[4]: Lancet Infect Dis - tet(X) review
[5]: Antimicrob Agents Chemother - tet(X4)
[6]: J Antimicrob Chemother - Stenotrophomonas
[7]: Clin Infect Dis - Enterococcus
[8]: EUCAST Tigecycline Breakpoints



Other Questions About Tigecycline :

What is the cost difference between brand name and generic tigecycline? Is tigecycline effective against bacterial pneumonia? How long is tigecycline patent protected? How does obesity impact tigecycline metabolism? How does tigecycline compare to other antibiotics for mrsa? Can you remind me of the typical tigecycline dose by itself? How do antacids chemically interact with tigecycline?




DrugPatentWatch - Make Better Decisions
© thinkBiotech LLC 2004 - 2026. All rights reserved. Privacy